IFCC Reference System for Measurement of Hemoglobin A1c in Human Blood and the National Standardization Schemes in the United States, Japan, and Sweden: A Method-Comparison Study
-
- Wieland Hoelzel
- Roche Diagnostics GmbH, Penzberg, Germany
-
- Cas Weykamp
- SKZL Queen Beatrix Hospital, Winterswijk, The Netherlands
-
- Jan-Olof Jeppsson
- Department of Clinical Chemistry, Malmo University Hospital, Lund University, Malmo, Sweden
-
- Kor Miedema
- Department of Clinical Chemistry, Isala Klinieken, NA 8000 GM Zwolle, The Netherlands
-
- John R Barr
- Centers for Disease Control and Prevention, Atlanta, GA
-
- Ian Goodall
- Department of Laboratory Medicine. Austin & Repatriation Medical Centre, Melbourne, Australia
-
- Tadao Hoshino
- Institute of Biopathological Medicine, Ono, Japan
-
- W Garry John
- Department of Clinical Biochemistry, Norfolk and Norwich University Hospital, Norwich, Norfolk, United Kingdom
-
- Uwe Kobold
- Roche Diagnostics GmbH, Penzberg, Germany
-
- Randie Little
- University of Missouri School of Medicine, Columbia, MO
-
- Andrea Mosca
- Department of Science and Biomedical Technology, University of Milan, Milan, Italy
-
- Pierluigi Mauri
- Institute of Biomedical Technology, Consiglio Nazionale Delle Ricerche, Milan, Italy
-
- Rita Paroni
- Istituto di Ricovero e Cura a Carattere Scientifico, Hospital San Raffaele, Milan, Italy
-
- Fransiscus Susanto
- German Diabetes Research Institute, Duesseldorf, Germany
-
- Izumu Takei
- Department of Laboratory Medicine, School of Medicine, Keio University, Tokyo, Japan
-
- Linda Thienpont
- Laboratory of Analytical Chemistry, Faculty of Pharmaceutical Sciences, University of Gent, Ghent, Belgium
-
- Masao Umemoto
- Standard Reference Center, Kawasaki, Japan
-
- Hsiao-Mei Wiedmeyer
- University of Missouri School of Medicine, Columbia, MO
説明
<jats:title>Abstract</jats:title><jats:p>Background: The national programs for the harmonization of hemoglobin (Hb)A1c measurements in the US [National Glycohemoglobin Standardization Program (NGSP)], Japan [Japanese Diabetes Society (JDS)/Japanese Society of Clinical Chemistry (JSCC)], and Sweden are based on different designated comparison methods (DCMs). The future basis for international standardization will be the reference system developed by the IFCC Working Group on HbA1c Standardization. The aim of the present study was to determine the relationships between the IFCC Reference Method (RM) and the DCMs.</jats:p><jats:p>Methods: Four method-comparison studies were performed in 2001–2003. In each study five to eight pooled blood samples were measured by 11 reference laboratories of the IFCC Network of Reference Laboratories, 9 Secondary Reference Laboratories of the NGSP, 3 reference laboratories of the JDS/JSCC program, and a Swedish reference laboratory. Regression equations were determined for the relationship between the IFCC RM and each of the DCMs.</jats:p><jats:p>Results: Significant differences were observed between the HbA1c results of the IFCC RM and those of the DCMs. Significant differences were also demonstrated between the three DCMs. However, in all cases the relationship of the DCMs with the RM were linear. There were no statistically significant differences between the regression equations calculated for each of the four studies; therefore, the results could be combined. The relationship is described by the following regression equations: NGSP-HbA1c = 0.915(IFCC-HbA1c) + 2.15% (r2 = 0.998); JDS/JSCC-HbA1c = 0.927(IFCC-HbA1c) + 1.73% (r2 = 0.997); Swedish-HbA1c = 0.989(IFCC-HbA1c) + 0.88% (r2 = 0.996).</jats:p><jats:p>Conclusion: There is a firm and reproducible link between the IFCC RM and DCM HbA1c values.</jats:p>
収録刊行物
-
- Clinical Chemistry
-
Clinical Chemistry 50 (1), 166-174, 2004-01-01
Oxford University Press (OUP)
